Key result
Short-term bisoprolol did not significantly reduce the incidence of perioperative myocardial injury compared to placebo in patients undergoing non-cardiac surgery (52.6% vs. 49.1%, p=0.706).
Why the study?
The protective role of preoperative beta-blockers in patients undergoing non-cardiac surgery was unknown.
Does short-term preoperative bisoprolol reduce perioperative myocardial injury in patients undergoing non-cardiac surgery?
RCT (n=112)
Double-blind
Block of four-randomization
No
Does short-term preoperative bisoprolol reduce perioperative myocardial injury in patients undergoing non-cardiac surgery?
Absolute Event Rate: 52.6% vs 49.1%
p-value: p=0.706
Short-term preoperative bisoprolol does not reduce perioperative myocardial injury in patients undergoing non-cardiac surgery but significantly increases the risk of intraoperative hypotension.
Short-term bisoprolol should not be used to prevent perioperative myocardial injury; reinforces guidelines against routine perioperative beta-blocker initiation.
The protective role of preoperative beta-blocker in patients undergoing non-cardiac surgery is unknown. We aimed to evaluate the effects of beta-blocker on perioperative myocardial injury in patients undergoing non-cardiac surgery. We consecutively enrolled 112 patients undergoing non-cardiac surgery. They were randomly allocated to receive bisoprolol or placebo given at least 2 days preoperatively and continued until 30 days after surgery. The primary outcome was incidence of perioperative myocardial injury defined by a rise of high-sensitive troponin-T (hs-TnT) more than 99th percentile of upper reference limit or a rise of hs-TnT more than 20% if baseline level is abnormal. Baseline characteristics were comparable between bisoprolol and placebo in randomized cohort Mean age was 62.5 ± 11.8 years and 76 (67.8%) of 112 patients were male. Among 112 patients, 49 (43.8%) underwent vascular surgery and 63 (56.2%) underwent thoracic surgery. The median duration of assigned treatment prior to surgery was 4 days (2-6 days). We did not demonstrate the significant difference in the incidence of perioperative myocardial injury [52.6% (30 of 57 patients) vs. 49.1% (27 of 55 patients), P = 0.706]. In addition, the incidence of intraoperative hypotension was higher in bisoprolol group than placebo group in patients undergoing non-cardiac surgery [70.2% (40 of 57 patients) vs. 47.3% (26 of 55 patients), P = 0.017]. We demonstrated that there was no statistically significant difference in perioperative myocardial injury observed between patients receiving bisoprolol and placebo who had undergone non-cardiac surgery.
No takes yet. Share an insight, caveat, or question.
Wongcharoen et al. (2021) conducted an RCT in Patients undergoing elective non-cardiac thoracic or vascular surgery (n=112). Bisoprolol vs. Placebo was evaluated on Incidence of perioperative myocardial injury within 3 days after surgery (defined by hs-TnT rise >99th percentile URL or >20% if baseline abnormal) (p=0.706). Short-term bisoprolol did not significantly reduce the incidence of perioperative myocardial injury compared to placebo in patients undergoing non-cardiac surgery (52.6% vs. 49.1%, p=0.706).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: